Informationes plurimae ― Latine

Urticaria vulgo manifestatur cum pruritu, eritemate et edemate. Aliquando subcutaneae papulae formantur. Curatio primum includit evitanda factora provocantia, si cognita sunt. Prima linea therapiae antihistaminica recentiora includit, quae ad dosim altam, si opus est, accommodari possunt. Alia medicamenta, sicut antihistamina vetusta, H2 obstructores, antagonista receptoris leukotrienici, antihistaminica potentiora, et cursus breves corticosteroidorum, adiici possunt. In casibus ubi urticaria persisteat, non obstante his modis, patientes ad specialistas referre possunt ad therapias additas, sicut omalizumab vel cyclosporine.
Urticaria commonly presents with intensely itchy raised welts. It is sometimes accompanied by swelling of the underlying tissues. Treatment primarily involves avoiding triggers, if known. First-line medication includes newer antihistamines, which can be adjusted to higher doses if needed. Other medications like older antihistamines, H2 blockers, leukotriene receptor antagonists, stronger antihistamines, and short courses of corticosteroids can be added as extra support. In cases where urticaria persists despite these measures, patients might be referred to specialists for additional therapies such as omalizumab or cyclosporine.

Haec recensio novas vias ad urticariam tractandam delineat et novas causas intellectus huius praebet.
This review outlines the latest guidelines for treating urticaria and offers new understandings of its causes.

Second-generation H1-antihistamines (e.g., cetirizine, loratadine, fexofenadine), Omalizumab, Ciclosporin, and short courses only of systemic corticosteroids